132 related articles for article (PubMed ID: 12738398)
1. Improvement of esophageal and gastric motility after 2-week treatment of oral erythromycin in patients with non-insulin-dependent diabetes mellitus.
Chang CT; Shiau YC; Lin CC; Li TC; Lee CC; Kao CH
J Diabetes Complications; 2003; 17(3):141-4. PubMed ID: 12738398
[TBL] [Abstract][Full Text] [Related]
2. Effects of oral erythromycin on upper gastrointestinal motility in patients with non-insulin-dependent diabetes mellitus.
Kao CH; Wang SJ; Pang DY
Nucl Med Commun; 1995 Sep; 16(9):790-3. PubMed ID: 7478413
[TBL] [Abstract][Full Text] [Related]
3. Effects of oral erythromycin on esophageal motility in patients with noninsulin-dependent diabetes mellitus.
Tsai SC; Kao CH; Pan DY; ChangLai SP; Wang SJ
Gaoxiong Yi Xue Ke Xue Za Zhi; 1995 Aug; 11(8):430-5. PubMed ID: 7674422
[TBL] [Abstract][Full Text] [Related]
4. Effect of oral erythromycin on patients with diabetic gastroparesis.
Pan DY; Chen GH; Chang CS; Ho KS; Poon SK; Huang CK; Kao CH; Wang SJ
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):447-51. PubMed ID: 7634182
[TBL] [Abstract][Full Text] [Related]
5. Erythromycin administration before sleep is effective in decreasing fasting hyperglycemia in type 2 diabetic patients.
Ueno N; Inui A; Asakawa A; Takao F; Ichibangase A; Komatsu Y; Kasuga M
Diabetes Care; 2001 Mar; 24(3):607. PubMed ID: 11289494
[No Abstract] [Full Text] [Related]
6. Oral erythromycin improves gastrointestinal motility and transit after subtotal but not total gastrectomy for cancer.
Altomare DF; Rubini D; Pilot MA; Farese S; Rubini G; Rinaldi M; Memeo V; D'Addabbo A
Br J Surg; 1997 Jul; 84(7):1017-21. PubMed ID: 9240156
[TBL] [Abstract][Full Text] [Related]
7. Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term.
Fiorucci S; Distrutti E; Gerli R; Morelli A
Am J Gastroenterol; 1994 Apr; 89(4):550-5. PubMed ID: 8147358
[TBL] [Abstract][Full Text] [Related]
8. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Horowitz M; Harding PE; Maddox AF; Wishart JM; Akkermans LM; Chatterton BE; Shearman DJ
Diabetologia; 1989 Mar; 32(3):151-9. PubMed ID: 2753246
[TBL] [Abstract][Full Text] [Related]
9. Upper gastrointestinal motility and symptoms in individuals with diabetes, prediabetes and normal glucose tolerance.
Boronikolos GC; Menge BA; Schenker N; Breuer TG; Otte JM; Heckermann S; Schliess F; Meier JJ
Diabetologia; 2015 Jun; 58(6):1175-82. PubMed ID: 25725624
[TBL] [Abstract][Full Text] [Related]
10. Erythromycin as a prokinetic agent in preterm infants.
Costalos C; Gounaris A; Varhalama E; Kokori F; Alexiou N; Kolovou E
J Pediatr Gastroenterol Nutr; 2002 Jan; 34(1):23-5. PubMed ID: 11753159
[TBL] [Abstract][Full Text] [Related]
11. [Effects of various prokinetic drugs on gastrointestinal transit times in patients with progressive systemic scleroderma].
Folwaczny C; Läritz M; Meurer M; Endres SP; König A; Schindlbeck N
Z Gastroenterol; 1997 Oct; 35(10):905-12. PubMed ID: 9432812
[TBL] [Abstract][Full Text] [Related]
12. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients.
Gonlachanvit S; Hsu CW; Boden GH; Knight LC; Maurer AH; Fisher RS; Parkman HP
Dig Dis Sci; 2003 Mar; 48(3):488-97. PubMed ID: 12757160
[TBL] [Abstract][Full Text] [Related]
13. Oral erythromycin accelerates impaired gastrointestinal motility after endoscopic mucosal resection.
Kawamura O; Kusano M; Shimoyama Y; Horikoshi T; Sekiguchi T; Mori M
Dig Dis Sci; 2007 Sep; 52(9):2211-20. PubMed ID: 17415637
[TBL] [Abstract][Full Text] [Related]
14. Effects of hyperinsulinaemia on erythromycin-induced gallbladder and gastric motility in normal subjects.
Cordoni MC; Distrutti E; Vermigli C; Marino C; Bottini P; Bosso R; Scionti L
Diabetes Nutr Metab; 2004 Feb; 17(1):72-5. PubMed ID: 15163131
[No Abstract] [Full Text] [Related]
15. Induced-hyperglycemia attenuates erythromycin-induced acceleration of hypertonic liquid-phase gastric emptying in type-I diabetic patients.
Petrakis IE; Chalkiadakis G; Vrachassotakis N; Sciacca V; Vassilakis SJ; Xynos E
Dig Dis; 1999; 17(4):241-7. PubMed ID: 10754365
[TBL] [Abstract][Full Text] [Related]
16. Effects of mitemcinal (GM-611), an orally active erythromycin-derived prokinetic agent, on delayed gastric emptying and postprandial glucose in a new minipig model of diabetes.
Ozaki K; Monnai M; Onoma M; Muramatsu H; Yogo K; Watanabe T; Oda Y; Katagiri K; Arakawa H; Itoh Z; Omura S; Takanashi H
J Diabetes Complications; 2008; 22(5):339-47. PubMed ID: 18413164
[TBL] [Abstract][Full Text] [Related]
17. Gastropyloric motor activity and the effects of erythromycin given orally after esophagectomy.
Nakabayashi T; Mochiki E; Garcia M; Haga N; Kato H; Suzuki T; Asao T; Kuwano H
Am J Surg; 2002 Mar; 183(3):317-23. PubMed ID: 11943134
[TBL] [Abstract][Full Text] [Related]
18. Oral mitemcinal (GM-611), an erythromycin-derived prokinetic, accelerates normal and experimentally delayed gastric emptying in conscious dogs.
Onoma M; Yogo K; Ozaki K; Kamei K; Akima M; Koga H; Itoh Z; Omura S; Takanashi H
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):35-42. PubMed ID: 18047625
[TBL] [Abstract][Full Text] [Related]
19. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis.
Erbas T; Varoglu E; Erbas B; Tastekin G; Akalin S
Diabetes Care; 1993 Nov; 16(11):1511-4. PubMed ID: 8299441
[TBL] [Abstract][Full Text] [Related]
20. Erythromycin improves glycaemic control in patients with Type II diabetes mellitus.
Ueno N; Inui A; Asakawa A; Takao F; Tani S; Komatsu Y; Itoh Z; Kasuga M
Diabetologia; 2000 Apr; 43(4):411-5. PubMed ID: 10819233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
